Anastrozole (1 mg) is a medication classified as an aromatase inhibitor, widely used in the management of hormone receptor‑positive breast cancer in postmenopausal women. Its primary role is to reduce estrogen levels in the body, since estrogen can stimulate the growth of certain types of breast cancer cells. By blocking the aromatase enzyme, which converts androgens into estrogen, Anastrozole effectively lowers circulating estrogen and slows or halts tumor progression. Clinically, it is prescribed as adjuvant therapy following surgery or radiation to minimize the risk of cancer recurrence, and it is also used in advanced or metastatic cases to control disease spread. Beyond oncology, Anastrozole has applications in hormone‑related conditions in men, such as managing gynecomastia or being explored in fertility treatments, where lowering estrogen can help rebalance hormonal activity. Its targeted mechanism makes it a modern alternative to older therapies like tamoxifen, offering a different side‑effect profile and treatment approach. Taken orally as a once‑daily tablet, Anastrozole provides a convenient and effective way to maintain long‑term control over estrogen‑dependent conditions, ultimately improving patient outcomes and quality of life under medical supervision.